Botensilimab/balstilimab demonstrate tumor shrinkage, biomarkers response in CRC

Weill Cancer Hub East established to investigate interplay between nutrition, metabolism, and immunotherapy

Four research institutions have partnered under the Weill Cancer Hub East

March 28, 2025

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Two recent studies by researchers from Regenstrief Institute and the Indiana University School of Medicine explore the effect of the pandemic on colorectal cancer screening tests and diagnostic colonoscopies in central Indiana.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Self-driving microscope solves previous challenges in microscopy

UT Southwestern Medical Center researchers developed a “self-driving” microscope that solves two challenges that have long plagued microscopy: 1) imaging living cells or organisms at dramatically different scales, and 2) following a specific structure or area of interest over long periods of time.

March 14, 2025

Vol.51 No.10

Drugs & Targets

University of New England licenses cancer biomarker test to Satya Diagnostics

The University of New England recently signed its first intellectual property license agreement with Satya Diagnostics—a company that recently received $100,000 in MaineHealth Bonfire Funding to help it achieve its goal of improving cancer detection and treatment in communities across the world.

March 07, 2025

Vol.51 No.09

Drugs & Targets

FDA accepts sBLA for Opdivo + Yervoy in CRC

FDA accepted Bristol Myers Squibb’s supplemental biologics license application for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

February 28, 2025

Vol.51 No.08

Clinical Roundup

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

January 31, 2025

Vol.51 No.04

Botensilimab/balstilimab demonstrate tumor shrinkage, biomarkers response in CRC

YOU MAY BE INTERESTED IN

Weill Cancer Hub East established to investigate interplay between nutrition, metabolism, and immunotherapy

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Self-driving microscope solves previous challenges in microscopy

University of New England licenses cancer biomarker test to Satya Diagnostics

FDA accepts sBLA for Opdivo + Yervoy in CRC

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login